31 August 2013Asia

Biopharmaceuticals: can India have its cake and eat it?

In late 2011, India adopted a National Manufacturing Policy to boost gross domestic product from 16 percent to 25 percent by 2022. The policy aims to aggressively increase domestic manufacturing capacity, especially in high technology areas.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

IndiaMart v CDSCO: A test of intermediary liability

31 March 2026 The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.

Asia

Part I: Ozempic goes generic as Novo’s key patent expires

20 March 2026 As the patent protecting semaglutide—the drug that made Novo Nordisk one of Europe's most valuable companies—expires in ten countries, the pressure mounts for prices and market leaders alike.

Asia

AstraZeneca partners with Chinese firm ahead of next obesity race

5 February 2026 The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.

More features

EU court under pressure to define SPC limits in patent row

Amneal acquires biopharma ahead of $300bn patent wave

Squires refuses to resurrect HydraFacial patent review

Simmons & Simmons makes senior Asia trademark hire

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

Patent office fee increases: What applicants must know

LSPN Awards USA: Meet the judges

Gilead to pay up to $5bn for antibody-drug conjugates push

Biopharmaceuticals: can India have its cake and eat it?

More on this story

Editor's picks

Editor's picks

More features